Leadership / Advisory Board
Clinical, scientific, and regulatory experts ensuring Mergic's multimodal AI platform meets the highest standards of accuracy, safety, and real-world clinical impact.
Mission
Our advisory board brings deep domain expertise to ensure every product is clinically validated, regulatory-ready, and safe for patient care.
Every Mergic AI model undergoes rigorous clinical validation overseen by advisory board members before deployment. Our advisors review study design, statistical methodology, performance metrics, and real-world safety monitoring to ensure platform accuracy exceeds clinical standards across patient populations.
Reviewing model performance, clinical trials, and real-world evidence generation across modalities.
Product roadmap, market priorities, partnership strategy, and clinical use-case identification.
HIPAA, FDA, EU MDR, and international regulatory pathway navigation and submission strategy.
Expertise
Spanning clinical medicine, computational biology, healthcare IT, regulatory law, digital pathology, and medical AI — with institutional affiliations at Stanford, MIT, Harvard, Johns Hopkins, and industry leaders.
Combined years of experience in AI-powered healthcare and genomics
Academic medical centers represented at advisory level
Distinct expertise domains: clinical, scientific, regulatory, and industry
Board convenes quarterly with ad-hoc sessions for urgent submissions
Scientific advisory
Director of Computational Genomics at the Broad Institute of MIT and Harvard. Pioneer in large-scale variant interpretation, multi-omic data integration, and population-scale genomics analysis. His work on rare disease variant prioritization directly informs Mergic Helix's GPU-accelerated variant calling and clinical interpretation pipelines.
Professor of Radiology at Stanford Medicine. Leading researcher in AI-assisted radiology interpretation and cross-modal imaging AI. Former chair of the ACR Data Science Institute. Oversees Mergic Vision validation studies across imaging modalities.
Chair of Digital Pathology at Johns Hopkins Medicine. Developing AI-assisted whole-slide image analysis and computational pathology workflows.
Clinical advisory
Former Chief Medical Officer of Illumina Clinical Services. Led clinical validation and regulatory strategy for next-generation sequencing diagnostics that received FDA clearance. Expert in clinical trial design for AI-assisted diagnostics, evidence generation for regulatory submissions, and bridging laboratory science to clinical implementation at scale.
Retrospective and prospective study design, endpoint selection, and statistical methodology for AI model validation.
Coordinating validation across diverse patient populations, imaging equipment, and clinical workflows.
Industry advisory
Former CTO of Flatiron Health (acquired by Roche for $1.9B). Architected real-world evidence platforms connecting EHR, imaging, and genomics data at scale for oncology research. Expert in building clinical data infrastructure that meets regulatory-grade quality standards while enabling AI-driven insights. Guides Mergic's architecture decisions for enterprise health system deployments.
Healthcare privacy attorney and former HHS Office for Civil Rights counsel. Expert in HIPAA, FDA software-as-medical-device regulation, AI governance frameworks, and international privacy law (GDPR, PIPEDA). Advises on Mergic Citadel governance architecture and regulatory submission strategy.
510(k), De Novo, breakthrough designation, and predetermined change control plans for AI/ML devices.
Areas of guidance
Study design, endpoint selection, evidence generation for regulatory submissions and peer-reviewed publication. Oversight of retrospective validation, prospective clinical trials, and post-deployment real-world monitoring across all Mergic products.
FDA breakthrough designation, 510(k) pathways, EU MDR compliance, and international medical device approvals.
Payor evidence requirements, health economics, reimbursement pathways, and clinical adoption strategy.
Fairness evaluation, algorithmic bias detection, equitable performance across diverse populations.
University collaborations, joint publications, and access to real-world clinical datasets for validation.
Why it matters
"AI in healthcare is not a software problem — it is a clinical safety problem. Every model that touches patient care must be validated with the same rigor we apply to drugs and devices. Independent advisory oversight is not optional; it is the minimum standard for responsible deployment."
"The convergence of imaging, genomics, and clinical data creates unprecedented diagnostic power — but also unprecedented risk. Cross-modal AI must be validated across every modality combination, every patient demographic, and every deployment context."
"Governance and compliance cannot be bolted on after the fact. They must be architectural decisions from day one."
Governance
The advisory board convenes quarterly to review product development, clinical validation progress, regulatory milestones, and strategic priorities. Special sessions are called for urgent regulatory submissions, clinical trial design reviews, or safety signals requiring immediate attention.
Specialized committees for imaging validation, genomics accuracy, trial design, regulatory strategy, and real-world evidence.
Advisors operate independently and may raise safety or ethical concerns directly to the board of directors.
Join the board
Mergic seeks advisory board members with deep expertise in precision oncology, cardiovascular imaging, rare disease genomics, pediatric diagnostics, international regulatory pathways, or health equity in AI. We value advisors who bring clinical credibility, academic networks, and a commitment to rigorous validation of AI systems in patient care.
Equity compensation, early product access, co-authorship on publications, and the opportunity to shape AI in precision medicine.
Contact our CMO at advisors@mergic.com with a CV and statement of interest.
Institutional affiliations
Advisory impact
The advisory board is not ceremonial. Every model shipped, every governance policy defined, and every clinical workflow designed has been validated by practicing clinicians and researchers on our board.
Advisors participate in quarterly product reviews, evaluate model benchmarks against clinical gold standards, review AI-assisted workflow designs before shipping, and validate that governance controls meet real-world compliance requirements. This isn't advisory in name only — it is the core of how Mergic builds software that clinical teams actually trust.
Advisors provide annotated clinical datasets and perform blind evaluation of model outputs against their own expert interpretation.
Clinical workflows in Vision, Helix, and Lumen are co-designed with specialty advisors before engineering begins — not retrofitted after.
Research collaboration
Advisory board members co-author validation studies on Mergic platform performance in clinical settings, submitted to RSNA, MICCAI, and ASHG.
De-identified benchmark datasets curated and annotated by advisory board clinicians for community model evaluation.
Advisory board members present Mergic clinical AI methodology at RSNA, HIMSS, MICCAI, ASHG, and AACR annually.
20+
Trusted by precision medicine leaders
Work with us
Book a demo to learn how our advisory board ensures clinical accuracy, regulatory compliance, and real-world validation across imaging, genomics, and clinical reasoning.